Other
The LAM Foundation
Total Trials
5
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed trials have results
Key Signals
1 recruiting1 with results
Enrollment Performance
Analytics
Phase 1
2(50.0%)
Phase 2
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT02432560Recruiting
Safety and Durability of Sirolimus for Treatment of LAM
Role: collaborator
NCT03150914Phase 3Active Not Recruiting
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Role: collaborator
NCT04388371Phase 1Completed
Glutamine PET Imaging in LAM
Role: collaborator
NCT02061397Phase 1Completed
Safety of Simvastatin in LAM and TSC
Role: collaborator
NCT00457808Phase 2Completed
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Role: collaborator
All 5 trials loaded